following an abbreviated submission:
rilpivirine/emtricitabine/tenofovir alafenamide (Odefsey®) is accepted for use within NHS Scotland.
Indication under review: treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg), infected with human immunodeficiency virus type 1 (HIV 1) without known mutations associated with resistance to the non nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine, and with viral load HIV 1 RNA ≤100,000 copies/mL.
For adult patients in whom emtricitabine/rilpivirine/tenofovir is an appropriate combination, Odefsey® (emtricitabine/rilpivirine/tenofovir alafenamide) offers an alternative to Eviplera® (emtricitabine/rilpivirine/tenofovir disoproxil) at no additional cost. Odefsey may also be used in patients from the age of 12 years.
Download detailed advice96KB (PDF)
Medicine details
- Medicine name:
- rilpivirine/emtricitabine/tenofovir alafenamide (Odefsey)
- SMC ID:
- 1189/16
- Indication:
- treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg), infected with human immunodeficiency virus type 1 (HIV 1) without known mutations associated with resistance to the non nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine, and with viral load HIV 1 RNA ≤100,000 copies/mL.
- Pharmaceutical company
- Gilead Sciences Ltd
- BNF chapter
- Infections
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 10 October 2016